In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...
Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...